Canada pharmacy body issues counselling standards for tirzepatide initiation

The pharmacy regulator in Canada has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.

The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.

The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.

Grete Skarsvåg, pharmacoeconomist, Norwegian Institute of Public Health, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."

The Journal has added the document to its practice index with the stated evidence grades recorded. We report guidance from the document, not from the accompanying summary.